NIH SBIR

NIH SBIR Fast-Track (Omnibus)

Supports United States small businesses with streamlined biomedical pathways from feasibility to continued development.

The NIH SBIR Fast-Track Omnibus is a combined Phase I and Phase II application mechanism that allows U.S. small businesses to submit both phases in a single application reviewed by a single study section. Issued jointly under R43 (Phase I component) and R44 (Phase II component) activity codes, Fast-Track awards cover the full Phase I feasibility period (typically six months, capped at $306,872) followed immediately by the Phase II development period (up to three years, capped at $2,045,816), for a combined maximum of approximately $2,352,688 in total costs without the 12–18 month funding gap that typically separates Phase I and Phase II applications. NIH distributes approximately $130 million per fiscal year through Fast-Track awards.

Fast-Track is designed for applicants who already possess strong preliminary data and a fully articulated Phase II plan at the time of submission. Reviewers evaluate both phases simultaneously and expect a complete Phase II scope of work, detailed milestones, and a credible commercialization strategy to be present in the initial application — not deferred. Eligibility requirements are the same as Phase II: U.S. small business, 500 or fewer employees, majority U.S.-owned, company performing at least 50% of the funded effort, and no clinical trials under this NOFO. Standard receipt dates are September 5, January 5, and April 5; the mechanism will reopen under successor NOFOs following the April 2026 reauthorization.

FY25 Fast-Track success rates were approximately 8%, lower than Phase II alone (22%), reflecting the higher bar set by simultaneous dual-phase review. Fast-Track is most advantageous when the Phase I work is low-risk and serves primarily to de-risk a well-understood development program rather than to answer a genuine open scientific question. Applicants with mature technology, strong institutional preliminary data, and a clear regulatory or commercialization pathway — who want to avoid the administrative gap and resubmission risk between Phase I and Phase II — represent the optimal profile for this mechanism.